18F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: Feasibility study in 60 patients - Abstract

PURPOSE: To retrospectively review data of a cohort of patients with biochemical progression after radical prostatectomy, treated according to a uniform institutional treatment policy, to evaluate toxicity and feasibility of high-dose salvage radiation therapy (80 Gy).

METHODS AND MATERIALS: Data on 60 patients with biochemical progression after radical prostatectomy between January 2009 and September 2011 were reviewed. The median value of prostate-specific antigen before radiation therapy was 0.9 ng/mL. All patients at time of diagnosis of biochemical recurrence underwent dynamic 18F-choline positron emission tomography/computed tomography (PET/CT), which revealed in all cases a local recurrence. High-dose salvage radiation therapy was delivered up to total dose of 80 Gy to 18F-choline PET/CT-positive area. Toxicity was recorded according to the Common Terminology Criteria for Adverse Events, version 3.0, scale.

RESULTS: Treatment was generally well tolerated: 54 patients (90%) completed salvage radiation therapy without any interruption. Gastrointestinal grade ≥2 acute toxicity was recorded in 6 patients (10%), whereas no patient experienced a grade ≥2 genitourinary toxicity. No grade 4 acute toxicity events were recorded. Only 1 patient (1.7%) experienced a grade 2 gastrointestinal late toxicity. With a mean follow-up of 31.2 months, 46 of 60 patients (76.6%) were free of recurrence. The 3-year biochemical progression-free survival rate was 72.5%.

CONCLUSIONS: At early follow-up, 18F-choline PET/CT-driven high-dose salvage radiation therapy seems to be feasible and well tolerated, with a low rate of toxicity.

Written by:
D'Angelillo RM, Sciuto R, Ramella S, Papalia R, Jereczek-Fossa BA, Trodella LE, Fiore M, Gallucci M, Maini CL, Trodella L.   Are you the author?
Radiation Oncology, Campus Bio-Medico University, Rome, Italy; Department of Nuclear Medicine, Regina Elena National Cancer Institute, Rome, Italy; Department of Urology, Regina Elena National Cancer Institute, Rome, Italy; Department of Radiation Oncology, European Institute of Oncology, Milan, Italy; Department of Health Sciences, University of Milan, Milan, Italy.  

Reference: Int J Radiat Oncol Biol Phys. 2014 Jul 29. pii: S0360-3016(14)00701-9.
doi: 10.1016/j.ijrobp.2014.05.050

PubMed Abstract
PMID: 25084612

UroToday.com Prostate Cancer Section







Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.